Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ricardo Garbe Habib.
Jacc-cardiovascular Interventions | 2015
Luciana Armaganijan; Rodolfo Staico; Dalmo Antonio Ribeiro Moreira; Renato D. Lopes; Paulo T.J. Medeiros; Ricardo Garbe Habib; Jônatas Melo Neto; Marcelo Katz; Dikran Armaganijan; Amanda Sousa; Felix Mahfoud; Alexandre Abizaid
OBJECTIVES This study aimed to assess 6-month outcomes in patients with implantable cardioverter-defibrillators (ICDs) undergoing renal sympathetic denervation (RSD) for refractory ventricular arrhythmias (VAs). BACKGROUND ICDs are generally indicated for patients at high risk of malignant VAs. Sympathetic hyperactivity plays a critical role in the development, maintenance, and aggravation of VAs. METHODS A total of 10 patients with refractory VA underwent RSD. Underlying conditions were Chagas disease (n = 6), nonischemic dilated cardiomyopathy (n = 2), and ischemic cardiomyopathy (n = 2). Information on the number of ventricular tachycardia (VT)/ventricular fibrillation (VF) episodes and device therapies (antitachycardia pacing/shocks) in the previous 6 months as well as 1 and 6 months post-treatment was obtained from ICD interrogation. RESULTS The median number of VT/VF episodes/antitachycardia pacing/shocks 6 months before RSD was 28.5 (range 1 to 106)/20.5 (range 0 to 52)/8 (range 0 to 88), respectively, and was reduced to 1 (range 0 to 17)/0 (range 0 to 7)/0 (range 0 to 3) at 1 month and 0 (range 0 to 9)/0 (range 0 to 7)/0 (range 0 to 3) at 6 months afterward, respectively. There were no major procedure-related complications. Two patients experienced sustained VT within the first week; in both cases, no further episodes occurred during follow-up. Two patients were nonresponders: 1 with persistent idioventricular rhythm and 1 with multiple renal arteries and incomplete ablation. Three patients died during follow-up. None of the deaths was attributed to VA. CONCLUSIONS In patients with ICDs and refractory VAs, RSD was associated with reduced arrhythmic burden with no procedure-related complications. Randomized controlled trials investigating RSD for treatment of refractory VAs in patients with increased sympathetic activity are needed.
Revista Brasileira de Cardiologia Invasiva | 2011
Luciana Armaganijan; Rodolfo Staico; Simone Rolim Fernandes Fontes Pedra; Dalmo A. Moreira; Sergio Braga; Fausto Feres; Jorge Eduardo Assef; Rodrigo Barreto; Ricardo Garbe Habib; Amanda Sousa; Aníbal Damonte; Carlos A. C. Pedra
BACKGROUND: Thrombus formation in the left atrial appendage (LAA) is the main cause of thromboembolic events in patients with non-valvular atrial fibrillation (AF). Oral anticoagulants are considered first-line therapy for stroke prevention in AF patients. Despite its proven efficacy, long-term oral anti-coagulation is associated to innumerous limitations. Percutaneous LAA closure has emerged as a new strategy for stroke prevention in high risk AF patients who are not candidates for long term oral anticoagulation therapy. METHODS: We report the initial experience with percutaneous occlusion of the LAA using the new AmplatzerTM Cardiac Plug (ACP - AGA Medical Corp., Golden Valley, USA) in patients with AF and CHADS2 score > 2 who were not eligible for anti-coagulation therapy. Procedures were carried out under general anesthesia and 3D transesophageal echocardiography monitoring in real time. RESULTS: Three male patients, mean age of 79 years and CHADS2 2, 3 and 5 scores had the device successfully implanted using a transeptal approach with no complications, resulting in immediate LAA occlusion and hospital discharge two days later. At the 50-day follow-up, all patients were clinically well with complete LAA occlusion and no complications at transthoracic echocardiography. CONCLUSIONS: Percutaneous LAA occlusion with the new ACP seems to be an attractive alternative to prevent thromboembolic events in patients with AF and contraindications or limitations for anticoagulation therapy.
Clinical Cardiology | 2018
Tiago Costa Bignoto; Dalmo Antonio Ribeiro Moreira; Ricardo Garbe Habib; Edileide de Barros Correia; Ricardo Carneiro Amarante; Tannas Jatene; Mário Barbosa Guedes Nunes; Tiago Senra; Luiz Eduardo Mastrocolla
Hypertrophic cardiomyopathy (HCM), a genetically transmitted disease, is the most common genetic cardiovascular disease. Current strategies to stratify risk are expensive and concentrated in wealthy centers. Twelve‐lead electrocardiography (ECG) is inexpensive, universally available, and can be readily used for Selvester QRS scoring, which estimates scar size. This study aimed to establish the relation between ECG scar quantification and myocardial fibrosis (extent of myocardial delayed enhancement) in multidetector computed tomography (MDCT).
Revista Brasileira de Cardiologia Invasiva | 2013
Rodolfo Staico; Luciana Armaganijan; Dalmo Antonio Ribeiro Moreira; Paulo de Tarso Jorge Medeiros; Ricardo Garbe Habib; Jônatas Melo Neto; Alexandre Abizaid
ABSTRACT Renal sympathetic denervation (RSD) has emerged as an adjunct strategy in the treatment of resistant hypertension. Several other clinical conditions are characterized by sympathetic hyperactivity and could theoretically benefit from RSD. We report the first case of RSD performed in Brazil in a patient with Chagas’ disease and refractory arrhythmia, treated by the EnligHTN® multi-electrode catheter.
Rev. Soc. Cardiol. Estado de Säo Paulo | 2003
Ricardo Garbe Habib; Rogério Braga Andalaft; Dalmo Antonio Ribeiro Moreira; Luis Roberto de Moraes; Carlos Anibal Sierra Reyes; Júlio César Gizzi
Revista Brasileira de Cardiologia Invasiva | 2013
Rodolfo Staico; Luciana Armaganijan; Dalmo Antonio Ribeiro Moreira; Paulo de Tarso Jorge Medeiros; Ricardo Garbe Habib; Jônatas Melo Neto; Alexandre Abizaid
European Heart Journal | 2018
Bruno Pereira Valdigem; R B Andalaft; Diana Moreira; L R Faria; F G Oliveira; D A Pimenta; E V B Ribeiro; I M Sa Junior; Luciana Armaganijan; Ricardo Garbe Habib; C F Da Silva
RELAMPA, Rev. Lat.-Am. Marcapasso Arritm | 2016
Claudia da Silva Fragata; Dalmo Antonio Ribeiro Moreira; Rogério Braga Andalaft; Ricardo Garbe Habib; Carolina Christianini Mizzaci; Kleber Rogério Serafim; Paulo Costa; Luciana Armaganijan; Bruno Pereira Valdigem
Rev. Soc. Cardiol. Estado de Säo Paulo | 2014
Dalmo Antonio Ribeiro Moreira; Ricardo Garbe Habib
RELAMPA, Rev. Lat.-Am. Marcapasso Arritm | 2014
Claudia da Silva Fragata; Dalmo Antonio Ribeiro Moreira; Rogério Braga Andalaft; Ricardo Garbe Habib; Heloísa Maria Khader; Paula Vargas de Saboya; Márcio Jansen de Oliveira Figueiredo; Ana Paula Damiano; Fernando Piza de Sousa Cannavan